Roche's Billion-Dollar Deal with Alnylam for Hypertension Drug
TL;DR Summary
Roche's $3 billion deal with Alnylam for the rights to a hypertension treatment demonstrates a renewed interest from large pharmaceutical companies in developing long-acting heart drugs, as the cardiovascular disease market has been overshadowed by cancer and other diseases.
Topics:business#alnylam#cardiovascular-disease#hypertension-treatment#long-acting-heart-drugs#pharmaceuticals#roche
- Roche's Alnylam deal shows drug firms interested in heart drugs STAT
- Roche enters partnership with Alnylam for hypertension therapy Reuters.com
- Roche signs onto Alnylam's mid-stage hypertension med for $310 million upfront FierceBiotech
- Roche Signs $2.8 Billion Alnylam Deal for Hypertension Drug Bloomberg
- View Full Coverage on Google News
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
0 min
vs 1 min read
Condensed
66%
115 → 39 words
Want the full story? Read the original article
Read on STAT